AFMDAffimed N.V.

Nasdaq affimed.com


$ 7.13 $ 0.01 (0.14 %)    

Friday, 14-Jun-2024 15:59:55 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 7.1
$ 7.08
$ 0.00 x 0
$ 0.00 x 0
$ 6.70 - $ 7.21
$ 2.24 - $ 8.95
578,232
na
108.11M
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 laidlaw--co-maintains-buy-on-affimed-raises-price-target-to-25

Laidlaw & Co. analyst Yale Jen maintains Affimed (NASDAQ:AFMD) with a Buy and raises the price target from $15 to $25.

 hc-wainwright--co-reiterates-buy-on-affimed-maintains-10-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price t...

 affimed-q1-eps-138-beats-154-estimate-sales-16834k-miss-134m-estimate

Affimed (NASDAQ:AFMD) reported quarterly losses of $(1.38) per share which beat the analyst consensus estimate of $(1.54) by 10...

 why-is-german-biotech-affimed-stock-soaring-on-monday

Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate a...

 why-affimed-shares-are-soaring
Why Affimed Shares Are Soaring
06/03/2024 16:58:38

Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 stud...

 affimed-shares-resume-trade
Affimed Shares Resume Trade
06/03/2024 16:35:15

 hc-wainwright--co-reiterates-buy-on-affimed-maintains-10-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price t...

 affimed-says-fda-granted-fast-track-designation-to-combination-of-its-innate-cell-engager-afm24-with-atezolizumab-for-egfr-wild-type-non-small-cell-lung-cancer

This is for the treatment of patients with advanced and/or metastatic non-small cell lung cancer (NSCLC) not harboring any acti...

 affimed-announces-acceptance-of-an-abstract-on-preclinical-data-of-its-innate-cell-engager-afm28-at-the-eha-2024-congress

Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid ...

 wells-fargo-maintains-overweight-on-affimed-lowers-price-target-to-25

Wells Fargo analyst Yanan Zhu maintains Affimed (NASDAQ:AFMD) with a Overweight and lowers the price target from $30 to $25.

 cantor-fitzgerald-reiterates-overweight-on-affimed

Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:AFMD) with a Overweight.

 hc-wainwright--co-maintains-buy-on-affimed-raises-price-target-to-10

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Affimed (NASDAQ:AFMD) with a Buy and raises the price targe...

 affimed-q4-eps-150-beats-167-estimate-sales-44455k-miss-170m-estimate

Affimed (NASDAQ:AFMD) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.67) by 10...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...